Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: scope who wrote (5747)	3/2/1998 11:20:00 PM
From: MissLil	Read Replies (1) \| Respond to of 23519

For those new to this thread: "Market has tested the product. Has not confidence on it's long success." Not many MDs on Wall Street. MDs on this thread generally agree on the value of this product, although others, such as the oral product from Pfizer, are expected to be valuable. "Given the fact that most of the profits are realized at the developmental stages, this dog is dead." This statement is incorrect in every respect. Why would anyone invest in an established pharmaceutical co. if this were true? "From the action of the stock,there is no more than 12 month life left." Presumably this is based on a technical analysis. Fundamental analysis would suggest a different picture. However, this stock is a long term play and not likely to have a radical upswing in the next few months, IMO. "Unfortunately,you are so much involved with it,your ego will not allow you to see you are wrong.Until is too late." Everyone must make his or her own investment decisions. EyeDoc makes reasonable statements. One may not agree with them, but they are worth considering. However, much of the market has the "Scope" mentality. This is both an opportunity and something to consider in one's investing. There is however, no proven cure for stupidity, although it's would be a great market opportunity.

To: scope who wrote (5747)	3/3/1998 8:22:00 AM
From: RT	Respond to of 23519

Scope, <<The market has tested the product and has no confidence in it's long term success. There is no more than 12 months left.>> Scope, Let me ask you a question? Has the real ED market ever tested Viagara? For a product that has not even been approved much less tested in the real market place, your comments regarding Vivus's demise, may be a bit premature. Furthermore, Vivus is testing improved formulations, that will rival direct needle injection. Just read Dr. Voss's recent posts.. It's extremely difficult at this time to determine the eventual outcome of Vivus's role in the ED market. With production constraints and the near term launch of Viagara, the sky is a bit cloudy. However, the games is not over until it's over. I'll stick around for the second half. RT